07:56 AM EDT, 09/02/2025 (MT Newswires) -- Arrowhead Pharmaceuticals ( ARWR ) said Tuesday it has signed a global licensing and collaboration agreement with Novartis ( NVS ) for its ARO-SNCA preclinical stage siRNA therapy to treat synucleinopathies, such as Parkinson's Disease.

When finalized, Arrowhead said it will receive $200 million upfront with eligibility for up to $2 billion in potential milestone payments and royalties on commercial sales.

The agreement also includes other collaboration targets that utilize Arrowhead's targeted RNAi Molecule platform, the company said.

Shares of Arrowhead gained more than 8% in recent Tuesday premarket activity. Novartis ( NVS ) was down 0.4%.